. 2019 Aug 28;25(32):4682–4695. doi: 10.3748/wjg.v25.i32.4682

Table 2.

Positron emission tomography in animal experiments of hepatocellular carcinoma

Isotopes	Half-life	Radiotracer	Year	First author	Animal models	Related notable findings	Limitations
¹⁸F	110 min	¹⁸F-FPGLU	2017	Sun et al[19]	Tumor-bearing mice (HCC SMCC-7721)	Radiochemical purity is higher than 95% with a specific activity of 30-40 GBq/μmol	Unstable in plasma, tumor, and urine
						Stable in vitro
						High uptake and retention in tumor
⁶⁴Cu	12.7 h	⁶⁴CuCl₂	2011	Lièvre et al[71]	Athymic mice bearing extrahepatic HCC xenografts	Increased ⁶⁴Cu radioactivity is well visualized	Abundant physiological distribution in liver
⁶⁴Cu	12.7 h	⁶⁴CuCl₂	2011	Lièvre et al[71]	Athymic mice bearing extrahepatic HCC xenografts	Useful for detection of intracranial HCC metastasis	Abundant physiological distribution in liver
⁶⁸Ga	68 min	⁶⁸Ga-NGR	2017	Gao et al[32]	Tumor-bearing mice (HCC SMCC-7721)	⁶⁸Ga-NGR could visualize CD13-positive tumors	The uptake performance of ⁶⁸Ga-NGR for poorly differentiated HCC needs further investigation
⁶⁸Ga	68 min	⁶⁸Ga-NGR	2017	Gao et al[32]	Tumor-bearing mice (HCC SMCC-7721)	⁶⁸Ga-NGR uptake is significantly higher than that of 18F-FDG in well-differentiated HCC xenografts
⁸⁹Zr	78.4 h	⁸⁹Zr-αGPC3	2014	Sham et al[79]	HepG2 tumor-bearing mice	Excellent specificity	Long half-life in the blood, leading to suboptimal imaging pharmacokinetics, poorer tumor penetration, and increased immunogenicity due to relatively large size and intact Fc regions
⁸⁹Zr	78.4 h	⁸⁹Zr-αGPC3	2014	Sham et al[79]	HepG2 tumor-bearing mice	Even smaller tumors (<1 mm) are able to be identified
		⁸⁹Zr-αGPC3-F(ab′)2	2014	Sham et al[80]	HepG2 tumor-bearing mice	Significantly reduces blood circulation time	Potential risk of fragment concentration in the kidneys, leading to organ dysfunction
		⁸⁹Zr-αGPC3-F(ab′)2	2014	Sham et al[80]	HepG2 tumor-bearing mice	Lower background liver uptake allows for early imaging
		⁸⁹Zr-DFO-1G12	2014	Yang et al[81]	HepG2 tumor-bearing mice	Specifically taken up by GPC3-positive HCC xenografts regardless of GPC3 expression levels	This probe should be further validated using a humanized anti-GPC3 antibody
		⁸⁹Zr-DFO-1G12	2014	Yang et al[81]	HepG2 tumor-bearing mice	High tumor-to-liver ratio
		⁸⁹Zr-Df-YY146-ZW800	2016	Hernandez et al[82]	HepG2 tumor-bearing mice	Excellent CD146-affinity, specificity, and stability	Bone-displaying PET signal is not matched by NIRF
		⁸⁹Zr-Df-YY146-ZW800	2016	Hernandez et al[82]	HepG2 tumor-bearing mice	Both PET and NIRF imaging are achieved	Bone-displaying PET signal is not matched by NIRF

HCC: Hepatocellular carcinoma; PET: Positron emission tomography;

¹⁸

F-FPGLU: N-(2-¹⁸F-fluoropropionyl)-L-glutamate;

⁶⁸

Ga-NGR: ⁶⁸Ga-labeled asparagine-glycine-arginine;

⁸⁹

Zr-αGPC3: ⁸⁹Zr-anti glypican-3; ⁸⁹Zr-αGPC3-F(ab’)2: ⁸⁹Zr-anti glypican-3-F(ab’)2; ⁸⁹Zr-DFO-1G12: ⁸⁹Zr-desferrioxamine-1G12; ⁸⁹Zr-Df-YY146-ZW800: ⁸⁹Zr- deferoxamine-YY146-ZW800; NIRF: Near-infrared fluorescence.